Central Alerting System
View Alert

Originator: National Patient Safety Alert - DHSC

Issue date: 03-Aug-2022 09:46:53

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Special Health Authorities
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • DHSC Supply Disruption - Medicines

Action category: Action

Title: Shortage of alteplase and tenecteplase injections

Broadcast content: There will be supply constraints facing alteplase (Actilyse®) 10mg, 20mg and 50mg injections for the remainder of 2022. Tenecteplase (Metalyse®) 10,000unit injections will go out of stock in the coming months. At present the situation is expected to improve in early 2023.

This National Patient Safety Alert contains further information and actions for providers.

***06 October***: the supply situation of alteplase has since improved. A Medicines Supply Notification has been published which supersedes the management advice provided in this National Patient Safety Alert. This notification can be accessed via this link.

Additional information: This National Patient Safety Alert is not relevant to Primary Care.

Alert reference: NatPSA/2022/006/DHSC

Action underway deadline: 05-Aug-2022

Action complete deadline: 10-Aug-2022


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency